AI Engines For more Details: Perplexity Kagi Labs You
Allergy Relief: Pheniramine maleate works by blocking the action of histamine, a substance in the body that causes allergy symptoms such as sneezing, itching, watery eyes, and runny nose. By blocking histamine receptors, pheniramine helps alleviate these symptoms and provides relief from allergic reactions.
Relief of Cold and Flu Symptoms: Pheniramine maleate is sometimes included in over-the-counter cold and flu medications to help relieve symptoms such as nasal congestion, sneezing, and runny nose. It can also help alleviate symptoms of cough associated with upper respiratory tract infections.
Sedation: Pheniramine maleate has sedative effects and may cause drowsiness or dizziness, particularly in some individuals. It is often used in nighttime cold and flu formulations to help promote sleep and relieve symptoms that may interfere with rest.
Dry Mouth: Dry mouth is a common side effect of pheniramine maleate. This occurs due to the anticholinergic effects of the medication, which can reduce saliva production. Patients should stay hydrated and may use sugar-free lozenges or gum to alleviate dry mouth symptoms.
Blurred Vision: Pheniramine maleate can cause temporary blurred vision or difficulty focusing, particularly at higher doses. Patients should use caution when performing tasks that require clear vision, such as driving or operating machinery, especially until they know how the medication affects them.
Urinary Retention: Pheniramine maleate may impair bladder function and lead to urinary retention, particularly in men with prostatic hypertrophy or individuals with pre-existing urinary tract conditions. Patients experiencing difficulty urinating should seek medical attention promptly.
Constipation: Constipation may occur as a result of pheniramine's anticholinergic effects, which can slow down bowel movements and reduce gastrointestinal motility. Increasing fluid intake and dietary fiber or using stool softeners may help alleviate constipation.
Increased Intraocular Pressure: Pheniramine maleate can increase intraocular pressure (pressure inside the eye) and may exacerbate glaucoma or worsen symptoms in individuals with pre-existing eye conditions. Patients with glaucoma should use pheniramine with caution and under the guidance of an eye care professional.
Interactions: Pheniramine maleate may interact with other medications, particularly central nervous system depressants such as alcohol, sedatives, and tranquilizers, leading to additive effects on sedation and drowsiness. Patients should avoid alcohol and use caution when combining pheniramine with other medications that cause drowsiness.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.4 | 0.3 | 13.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.2 | 2.3 | 0.39 |
| Allergies | 6.1 | 2.9 | 1.1 |
| Allergy to milk products | 1.7 | 1.6 | 0.06 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.2 | 7.4 | -0.19 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 0.7 | 5.14 |
| Ankylosing spondylitis | 4.8 | 1 | 3.8 |
| Anorexia Nervosa | 1.3 | 2.9 | -1.23 |
| Antiphospholipid syndrome (APS) | 1.6 | 0.3 | 4.33 |
| Asthma | 4.4 | 3.3 | 0.33 |
| Atherosclerosis | 1.5 | 2.4 | -0.6 |
| Atrial fibrillation | 3.7 | 3.1 | 0.19 |
| Autism | 9 | 10.5 | -0.17 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.1 | 1.1 | |
| Bipolar Disorder | 1.8 | 1.1 | 0.64 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.6 | 2.1 | -2.5 |
| Carcinoma | 3.5 | 2.3 | 0.52 |
| Celiac Disease | 2.9 | 4 | -0.38 |
| Cerebral Palsy | 1.9 | 1 | 0.9 |
| Chronic Fatigue Syndrome | 3.7 | 6.8 | -0.84 |
| Chronic Kidney Disease | 4 | 2.8 | 0.43 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1.7 | -0.7 |
| Chronic Urticaria (Hives) | 1.4 | 1.8 | -0.29 |
| Coagulation / Micro clot triggering bacteria | 1.4 | 1 | 0.4 |
| Cognitive Function | 2.2 | 1.6 | 0.38 |
| Colorectal Cancer | 6 | 2.3 | 1.61 |
| Constipation | 1.7 | 0.7 | 1.43 |
| Coronary artery disease | 1.9 | 3 | -0.58 |
| COVID-19 | 9.3 | 12.5 | -0.34 |
| Crohn's Disease | 8 | 6.3 | 0.27 |
| Cushing's Syndrome (hypercortisolism) | 0.8 | -0.8 | |
| cystic fibrosis | 0.7 | 1.7 | -1.43 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 2 | 1.1 | 0.82 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 10.6 | 10.1 | 0.05 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.8 | 1.8 | 0 |
| Endometriosis | 3 | 1.8 | 0.67 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 3.1 | 2.4 | 0.29 |
| erectile dysfunction | 1.1 | 0.3 | 2.67 |
| Fibromyalgia | 2.9 | 2.4 | 0.21 |
| Functional constipation / chronic idiopathic constipation | 5.9 | 3.9 | 0.51 |
| gallstone disease (gsd) | 3.3 | 1.3 | 1.54 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 1.2 | 0.08 |
| Generalized anxiety disorder | 2.5 | 2.5 | 0 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.8 | 1 | 0.8 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.2 | 1.7 | 0.88 |
| Heart Failure | 3.7 | 2.1 | 0.76 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 0.9 | 0.3 | 2 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | 0 |
| hyperglycemia | 1.9 | 2.2 | -0.16 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.5 | 6.3 | -0.4 |
| Hypothyroidism | 0.5 | 0.7 | -0.4 |
| Hypoxia | 3.1 | 0.3 | 9.33 |
| IgA nephropathy (IgAN) | 1 | 5.3 | -4.3 |
| Inflammatory Bowel Disease | 7.1 | 10.2 | -0.44 |
| Insomnia | 1.9 | 3.2 | -0.68 |
| Intelligence | 1.5 | 0.6 | 1.5 |
| Intracranial aneurysms | 0.9 | 0.6 | 0.5 |
| Irritable Bowel Syndrome | 7.7 | 6 | 0.28 |
| ischemic stroke | 2.4 | 1.7 | 0.41 |
| Liver Cirrhosis | 7.1 | 4.8 | 0.48 |
| Long COVID | 7.5 | 8 | -0.07 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.4 | 1.3 | 0.08 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 1.1 | 2.2 | -1 |
| ME/CFS without IBS | 0.9 | 2.4 | -1.67 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2 | 1 | 1 |
| Metabolic Syndrome | 7.8 | 8.7 | -0.12 |
| Mood Disorders | 10.7 | 7.7 | 0.39 |
| multiple chemical sensitivity [MCS] | 1.1 | 0.1 | 10 |
| Multiple Sclerosis | 5.8 | 6.2 | -0.07 |
| Multiple system atrophy (MSA) | 1.8 | 0.4 | 3.5 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 3.6 | -3.6 | |
| Neuropathy (all types) | 0.9 | 2.2 | -1.44 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.3 | 5.5 | -0.04 |
| NonCeliac Gluten Sensitivity | 1.6 | 0.6 | 1.67 |
| Obesity | 10.9 | 7.5 | 0.45 |
| obsessive-compulsive disorder | 5.7 | 4 | 0.43 |
| Osteoarthritis | 3 | 1.4 | 1.14 |
| Osteoporosis | 1.9 | 1.9 | 0 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 7.9 | 7.2 | 0.1 |
| Polycystic ovary syndrome | 5.9 | 2.8 | 1.11 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.4 | -0.17 |
| Primary sclerosing cholangitis | 2.2 | 2.6 | -0.18 |
| Psoriasis | 3.5 | 4 | -0.14 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.6 | 4.4 | 0.73 |
| Rosacea | 0.3 | 0.7 | -1.33 |
| Schizophrenia | 6.3 | 3.3 | 0.91 |
| scoliosis | 0.4 | 0.9 | -1.25 |
| Sjögren syndrome | 3.2 | 3.1 | 0.03 |
| Sleep Apnea | 1.6 | 1.3 | 0.23 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0.6 | 1.33 |
| Stress / posttraumatic stress disorder | 2.9 | 2.7 | 0.07 |
| Systemic Lupus Erythematosus | 4 | 1.8 | 1.22 |
| Tic Disorder | 1.1 | 1.8 | -0.64 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 4.6 | 3.8 | 0.21 |
| Type 2 Diabetes | 8.6 | 7.6 | 0.13 |
| Ulcerative colitis | 5.1 | 8.4 | -0.65 |
| Unhealthy Ageing | 4.7 | 2.9 | 0.62 |
| Vitiligo | 2.2 | 1.8 | 0.22 |
